NuCana (NASDAQ:NCNA) Issues Earnings Results

NuCana (NASDAQ:NCNA) issued its quarterly earnings results on Thursday. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.43) by $2.11, Zacks reports.

NuCana Trading Down 2.2 %

Shares of NASDAQ:NCNA opened at $0.79 on Friday. The stock’s 50-day moving average price is $0.97 and its two-hundred day moving average price is $1.54. NuCana has a 12-month low of $0.75 and a 12-month high of $10.79. The firm has a market cap of $2.09 million, a price-to-earnings ratio of -0.08 and a beta of 0.89.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.